| Literature DB >> 35956858 |
Hajo Idriss1,2, Babeker Siddig3,4, Pamela González Maldonado5, H M Elkhair1, A I Alakhras1,6, Emad M Abdallah7, Pablo Hernán Sotelo Torres5, Amin O Elzupir1,2.
Abstract
Siddha medicine is one of the oldest medical systems in the world and is believed to have originated more than 10,000 years ago and is prevalent across ancient Tamil land. It is undeniable that inhibitor preferences rise with increasing solubility in water due to the considerations pertaining to the bioavailability and the ease of which unabsorbed residues can be disposed of. In this study, we showed the phytochemical discrimination of Saussurea costus extracted with water at room temperature as a green extraction procedure. A total of 48 compounds were identified using gas chromatography-mass spectrometry (GC-MS). The fatty acids had a high phytochemical abundance at 73.8%, followed by tannins at 8.2%, carbohydrates at 6.9%, terpenoids at 4.3%, carboxylic acids at 2.5%, hydrocarbons at 2.4%, phenolic compounds at 0.2%, and sterols at 1.5%. Of these compounds, 22 were docked on the active side and on the catalytic dyad of His41 and Cys145 of the main protease of SARS-CoV-2 (Mpro). Eight active inhibitors were carbohydrates, five were fatty acids, three were terpenoids, two were carboxylic acids, one was a tannin, one was a phenolic compound, and one was a sterol. The best inhibitors were 4,8,13-Cyclotetradecatriene-1,3-diol, 1,5,9-trimethyl-12-(1-methylethyl), Andrographolide, and delta.4-Androstene-3.beta.,17.beta.-diol, with a binding affinity that ranged from -6.1 kcal/mol to -6.5 kcal/mol. The inhibitory effect of Saussurea costus of SARS-CoV-2 entry into the cell was studied using a pseudovirus with Spike proteins from the D614G variant and the VOC variants Gamma and Delta. Based on the viral cycle of SARS-CoV-2, our results suggest that the Saussurea costus aqueous extract has no virucidal effect and inhibits the virus in the events after cell entry. Furthermore, the biological activity of the aqueous extract was investigated against HSV-1 virus and two bacterial strains, namely Staphylococcus aureus ATCC BAA 1026 and Escherichia coli ATCC 9637. According to this study, an enormous number of water-soluble inhibitors were identified from Saussurea costus against the Mpro, and this is unprecedented as far as we know.Entities:
Keywords: COVID-19; GC-MS profiling; Saussurea costus; coronavirus SARS-CoV-2; main protease; molecular docking
Mesh:
Substances:
Year: 2022 PMID: 35956858 PMCID: PMC9370511 DOI: 10.3390/molecules27154908
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Phytochemicals in water-extracted compounds from Saussurea costus as identified by GC-MS.
Figure 2The crystal structure of the main protease of SARS-CoV-2 (PDB ID: 6Y2E).
The binding affinity of the extracted compounds active against 3-chymotrypsin-like protease (3CLpro).
| Compound ID/Class | Structure | Binding Affinity | Hydrogen Bond | van der Waals |
|---|---|---|---|---|
| Cmd1/carbohydrate |
| −4.7/ | GLU 166, HIS 164, HIS 163 | HIS 164, MET 165, HIS 163, LEU 141, ASN 142, GLU 166, PHE 140, SER 144, CYS 145 |
| Cmd2/carbohydrate |
| −3.9/ | HIS 163 | HIS 163, MET 165, GLU 166, SER 144, ASN 142, HIS 164, PHE 140 |
| Cmd3/carbohydrate |
| −4.3/ | HIS 163 | GLU 166, HIS 163, MET 165, HIS 164, ASN 142, LEU 141, PHE 140, CYS 145 |
| Cmd5/carbohydrate |
| −4.4/ | HIS 163, GLU 166 | HIS 163, MET 49, GLU 166, MET 165, HIS 41, GLN 189 |
| Cmd6/carboxylic acid |
| −3.8/ | HIS 163, GLU 166, PHE 140 | GLU 166, MET 165, CYS 145, HIS 163, ASN 142, SER 144, PHE 140, LEU 141 |
| Cmd7/carbohydrate |
| −5.0/ | HIS 163 | HIS 163, GLU 166, PHE 140, MET 165, HIS 164, CYS 145, ASN 142, SER 144, LEU 141 |
| Cmd8/fatty acid |
| −4.3/ | HIS 163, GLU 166 | HIS 163, GLU 166, MET 165, HIS 164, PHE 140, MET 49, CYS 145, ASN 142, SER 144, LEU 141 |
| Cmd11/carbohydrate |
| −4.9/ | - | HIS 163, GLU 166, MET 165, HIS 164, PHE 140, LEU 141, CYS 145, ASN 142, SER 144 |
| Cmd12/tannins |
| −4.6/ | HIS 164 | HIS 163, HIS 164, MET 165, GLU 166, PHE 140, LEU 141, ASN 142, SER 144, CYS 145 |
| Cmd13/carbohydrate |
| −4.3/ | PHE 140, HIS 163 | HIS 163, HIS 164, MET 165, GLU 166, PHE 140, LEU 141, ASN 142, SER 144, CYS 145, HIS 41 |
| Cmd15/fatty acid |
| −4.2/ | HIS 163 | HIS 163, HIS 164, MET 165, GLU 166, PHE 140, LEU 141, GLY 143, ASN 142, SER 144, CYS 145 |
| Cmd18/Phenolic Compound |
| −4.9/ | HIS 164, GLU 166 | GLN 189, PRO 168, THR 190, HIS 164, MET 165, GLU 166, MET 49, HIS 41, CYS 145 |
| Cmd20/carbohydrate |
| −5.1/ | GLY 143 | MET 49, GLU 166, ASN 142, GLY 143, GLN 189, MET 165, LEU 141, HIS 41, CYS 145 |
| Cmd21/Carboxylic acid |
| −4.3/ | GLU 166, GLY 143 | GLY 143, ASN 142, MET 49, THR 26, LEU 27, HIS 41, HIS 164, GLU 166, GLN 189, MET 165, CYS 145 |
| Cmd26/Fatty acid |
| −4.2/ | HIS 163, SER 144 | SER 144, HIS 163, THR 25, LEU 27, GLU 166, GLN 189, ASN 142, MET 49, PHE 140, LEU 141 |
| Cmd30/Terpenoid |
| −5.2/ | - | MET 49, THR 25, THR 26, LEU 27, HIS 41, ASN 142, CYS 145, HIS 164 |
| Cmd34/Hydrocarbon |
| −6.3/ | GLU 166 | GLU 166, ASN 142, PRO 168, PHE 140, LEU 141, HIS 163, MET 165, ASN 142, CYS 145, LEU 167, HIS 164, GLN 189 |
| Cmd35/Terpenoid |
| −6.3/ | GLU 166 | THR 25, MET 165, GLU 166, GLN 189, ASN 142, THR 45, SER 46, MET 49, CYS 44, HIS 41, CYS 145, THR 24 |
| Cmd38/Fatty acid |
| −3.7/ | HIS 163 | HIS 163, GLU 166, MET 49, SER 144, GLN 189, PHE 140, LEU 141, ASN 142, HIS 41, HIS 164, MET 165 |
| Cmd40/Terpenoid |
| −5.4/ | HIS 164 | GLU 166, MET 49, GLN 189, ASN 142, MET 165, CYS 145, HIS 164 |
| Cmd41/Fatty acid |
| −4.3/ | HIS 163, PHE 140 | HIS 163, ASN 142, SER 144, LEU 141, PHE 140, LEU 27, GLN 189, MET 49, THR 25, THR 26, GLU 166, CYS 145, GLY 143, HIS 41, MET 165 |
| Cmd42/Sterol |
| −6.5/ | - | MET 49, HIS 163, ASN 142, SER 144, LEU 141, PHE 140, LEU 27, GLN 189, THR 25, THR 26, GLU 166, CYS 145, GLY 143, HIS 41, MET 165 |
Figure 3The active inhibiter docked with the active sites of the main protease of SARS-CoV-2.
Figure 4Negative zone of inhibition of Saussurea costus aqueous extract (100 mg/mL) (T) compared to chloramphenicol (2.5 mg/mL) (C1) against tested bacteria.
Figure 5Antiviral activity of Saussurea costus aqueous extract against SARS-CoV-2. HEK−293T ACE2 cells were infected with the corresponding Spike-pseudotyped virus in the presence and absence of the extract. After 24 h, the luciferase activity was measured. The % of inhibition was determined as the ratio between treated and untreated cells.
Figure 6Antiherpetic activity and cytotoxicity of Saussurea costus aqueous extract. (A) Vero cells were incubated with increasing concentrations of the extract, and after 72 h, the cytotoxicity was measured as described in Section 2. (B) Vero cells were infected at MOI 1.5 with HSV-1 and incubated with increasing concentrations of the extract. After 72 h, the virus genome production was quantitated in the supernatant by qPCR. The % of inhibition was determined as the ratio between treated and untreated infected cells. Data are expressed as mean +/− SD for n = 2.
Figure 7Time of addition assay of Saussurea costus aqueous extract. Vero cells were infected at MOI 1.5 and incubated with the extract at different times during the infection as is described in Section 2. After 24 h.p.i, the virus genome production was quantitated in the supernatant by qPCR. The % of inhibition was determined as the ratio between treated and untreated infected cells. Data are expressed as mean +/− SD for n = 3.